Microsoft word - publications-for-robert-clarke-2-11-2009.doc

Publications for Robert Clarke
1991

1 Clarke R, Daly L, Robinson K, Naughton E, Cahalane S, Fowler B, Graham I.
Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
2 Clarke R, Mayo G, Price P, FitzGerald G. Suppression of thromboxane A2 but not of
systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325:1137-41.
3 Clarke R, Mayo G, FitzGerald G, Fitzgerald D. Combined administration of aspirin and a
specific thrombin inhibitor in man. Circulation 1991;83:1510-8.
4 Clarke R. Indapamide: a diuretic of choice for treatment of hypertension? Am J Med Sci
Clarke R, Graham I. Homocysteinaemia and vascular disease. J R Coll Phys
Clarke R, Robinson K, Keane F, O’Briain S, Graham I. Hyperhomocysteinemia
and multiple aneurysms. Post Grad Med J 1991;67:186-8.
1992

7 Clarke R, McLaughlin M, Martin E, Graham I. The heart disease of Friedreich's ataxia: a
clinical, electrocardiographic and echocardiographic assessment. J R Coll Phys Irl 1992;21:271-4.
8 Clarke R, Fitzgerald D, Brien C O, Farrell C O, Roche G, Parker R, Graham I.
Hyperhomocysteinemia: an independent risk factor for extracranial carotid artery atherosclerosis. Ir Med Sci 1992;161:61-5.
9 Clarke R, Naughten E, Cahalane S, Sullivan K O, Mathias P, McColl T, Graham I. The role
of free radicals as mediators of endothelial injury in hyperhomocysteinemia. Ir J Med Sci 1992;161:561-4.
1993

10 Hart J, Clarke R, on behalf of the Ireland-Netherlands Lisinopril Study Group. An ACE
Inhibitor versus a Calcium antagonist in the treatment of mild to moderate hypertension: A multicenter study. Post Grad Med J 1993;69:450-6. 1995

11 Parish S, Collins R, Peto R, Youngman L, Jayne K, Clarke R et al. Cigarette smoking, tar
yields, and non-fatal myocardial infarction: 14000 cases and 32000 controls in the United Kingdom. Br Med J 1995;311:471-77.
1997

12 Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: a
quantitative meta-analysis of the metabolic ward studies. Br Med J 1997;314:112-7. 13 Clarke R, Breeze E, Sherliker P et al. Design, objectives and lessons from a 25-year follow-
up resurvey of survivors in the Whitehall study of London Civil Servants. J Epidemiol Comm Health 1998;52:364-9. 14 Clarke R, Frost C, Leroy V, Collins R, for the Homocysteine Lowering Trialists'
Collaboration. Blood homocysteine lowering and folic acid based supplements: a systematic overview of the randomized trials. Br Med J 1998;316:894-8.
15 Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, Ueland PM, Khaw K-T.
Variability and determinants of plasma total homocysteine levels in an elderly population. Clin Chem 1998;44:102-7.
16 Clarke R, Smith AD, Jobst K, Sutton L, Refsum H, Ueland PM. Plasma homocysteine,
folate and vitamin B-12 as risk factors for confirmed Alzheimer’s disease. Arch Neurol 1998;55:1449-55.
17 Clarke R. Homocysteine and cardiovascular disease: an in-depth review. J Cardiovasc Risk

18 Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B-6 reduce
cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998;5:249-55.
1999
19 Frost C, Clarke R, Beacon H. Use of hierarchical models for meta-analysis: Experience in
the metabolic ward studies of diet and blood cholesterol. Stats in Med 1999;18:1657-76. 20 Clarke R, Shipley M, Collins R, Marmot M, Peto R. Underestimation of risk associations due
to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-53.
21 Clarke R. An overview of the homocysteine lowering clinical trials. In Robinson K, Kluwer

2000

22 Nexo E, Engbaek F, Ueland PM, Westby C, O'Gorman P, Johnston C, Kase BF,
Guttormsen AB, Alfheim I, McPartlin J, Smith D, Møller J, Rasmussen K, Clarke R, Scott
JM, Refsum H. Evaluation of novel assays in clinical chemistry: quantification of plasma
total homocysteine. Clin Chem 2000;46:1150-6.

23 Clarke R, Breeze E, Youngman L, Sherliker P, Bell P, Shah S, Shipley M, Collins R, Leon
D, Marmot M, Fletcher A. Re-survey of the Whitehall study of London civil servants: changes in risk factors for cardiovascular disease during 29 years of fol ow-up. J Cardiovasc Risk 2000;7:251-7.
24 Devlin AM, Ling E-H, Peerson JM, Fernando S, Clarke R et al. Glutamate carboxypeptidase
II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Human Mol Genet 2000;9:2837-44.
25 Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the
randomized trials of homocysteine-lowering vitamin supplements. Seminars in Thrombosis and Haemostasis 2000;26:341-8.
26 Clarke R, Joachim C, Esiri M, Morris J, Bungay H, Molyneux A, Budge M, Frost C, King E,
Barnetson L, Smith AD. Leukoaraiosis at presentation and disease progression during fol ow-up in histologically confirmed cases of dementia. Ann NY Acad Sci 2000; 903: 497-500. 2001

27 Breeze E, Fletcher AE, Leon DA, Marmot MG, Clarke R, Shipley MJ. Socioeconomic
disadvantage persists into old age: self-reported morbidity in a 29 year follow-up of the Whitehall Study. Am J Publ Health 2001;91:277-283.
28 Clarke R, Frost C. Dietary fat, blood lipids and coronary heart disease risk. In Nutritional
Health: Strategies for disease prevention. Wilson T, Temple N, (Eds), Humana Press Inc, Totowa, NJ 2001.
29 Clarke R. Prevention of vitamin B-12 deficiency in old age. Am J Clin Nutr 2001;73:151-2.
30 Clarke R, Stansbie D. Assessment of homocysteine as a cardiovascular risk factor in
clinical practice. Ann Clin Biochem 2001;38: 624-632.
31 Clarke R, Lewington S, Donald A, Johnston C, Refsum H, Stratton I, Jacques P, Breteler
MMB, Holman R. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 2001;8:363-9.
32 Clarke R. Design of clinical trials to test the homocysteine hypothesis of vascular disease.
In Homocysteine in Health and Disease, Carmel R and Jacobsen DW (eds), Cambridge University Press 2001.
2002

33 Clarke R, Lewington L, Youngman L, Sherliker P, Peto P, Collins R. Underestimation of
the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J 2002;23:286-293.
34 Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MBE.
Homocysteine, silent brain infarcts and white matter lesions: the Rotterdam Scan Study Ann Neurology 2002; 51:285-289.
35 Clarke R, Lewington S, Donald A and Collins R for the Homocysteine Studies
Collaboration. Homocysteine and risk of ischemic heart disease and stroke. 6000 events in 30 observational studies JAMA 2002; 288:2015-2022.
36 Lewington S, Clarke R, Quizilbash N, Peto R, Collins R for the Prospective Studies
Col aboration. Age-specific relevance of usual blood pressure to vascular mortality: One million adults in 61 prospective studies. Lancet 2002; 360:1903-13.
37 Clarke R, Commentary: An updated review of the published studies of homocysteine and
cardiovascular disease. Int J Epidemiol 2002; 31:70-71.
38 Prins ND, Den Heijer T, van Dijk EJ, Jolles J, Koudstaal PJ, Hofman A, Clarke R, Breteler
MMB. Homocysteine and cognitive function in the elderly: The Rotterdam study. Neurology 2002; 59: 1375-80. 39 Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C to T
polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-2031. 40 Huxley R, Lewington S, Clarke R. Cholesterol, coronary heart disease and stroke: a review
of published evidence from observational studies and randomized controlled trials. Seminars Vascular Med 2002; 2: 315-323.
41 Clarke R, Lewington S. Homocysteine and risk of heart disease and stroke. Seminars in
Vascular Medicine 2002; 3:391-399. 42 de Jager CA, Budge M, Clarke R. Utility of TICS-M to assess cognitive function in older
adults. Int J Geriatr Psychiatr 2002; 8:318-24. 43 Heart Protection Study Col aborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with Simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002:360:7-22. 44 Heart Protection Study Col aborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002:360:23-33.
45 Clarke R, Armitage J. Antioxidant vitamins and risk of cardiovascular disease. Cardiovasc
Drugs and therapy. 2002; 5:411-15.
2003

46 Lewington S, Thomsen T, Davidsen M, Clarke R. Regression dilution bias in blood
pressure and blood lipids in the Glostrup cohort and Framingham studies J Cardiovasc Risk 2003; 10:143-8.
47 den Heijer T, Vermeer S, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MMB.
Homocysteine, medial temporal lobe and generalised brain atrophy on MRI of non-demented elderly. Brain 2003; 126:170-5.
48 Clarke R, Lewington S, Landray M. Homocysteine, renal function and risk of cardiovascular
disease. Kidney International 2003; 84:5131-133.
49 Clarke R, Refsum H, Birks et al. Screening for vitamin B12 and folate deficiency in older
people. Am J Clin Nutr 2003; 77:1241-7.
50 Clarke R, Harrison G, Richards S, for the VITAL Trial Collaborative Group. Effect of
vitamins and aspirin treatment on markers of platelet activation, oxidative stress and homocysteine in people with dementia. J Internal Medicine 2003; 254:67-75.
51 van Oort FVA, Boonstra AM, Brouwer I, Clarke R, West CE, Katan MB, Verhoef P. Folic
acid and plasma homocysteine reduction in older adults: a dose-finding study. Am J Clin Nutr 2003; 77:1318-23.
52 Clarke R, Lewington S. How important are elevated homocysteine levels and the MTHFR
C677T→T genotype for coronary artery disease? Harrison’s Textbook of Medicine 2003; Online.
2004

53 Clarke R, J Grimley Evans, Refsum H et al. Vitamin B12 and folate deficiency in older
people. Age and Aging 2004; 33:34-41.
54 Refsum H, Smith A D, Ueland P M, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F,
Schneede J, McPartlin C, Scott J M. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50:30-32. 55 PROCARDIS Consortium. A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur J Human Genet 2004;12:770-774. 2005
56 Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous
thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;2:1-8. 57 Clarke R. Homocysteine. In Stanner S (Editor).Cardiovascular Disease: Diet, Nutrition and
Emerging Risk Factors. British Nutritional Foundation, London. Blackwell Scientific Publications 2005. 58 Melse-Boonstra A, Holm PA, Ueland PM, Olthof M, Clarke R, Verhoef P. Betaine as a
determinant of fasting total homocysteine concentration and the effect of folic acid supplementation. Am J Clin Nutr 2005;81:1378-82. 59 Eussen SJPM, deGroot CPGM, Clarke R, Schneede J, Ueland PM, Hofnagels WHL, van
Staveren WA. Oral vitamin B12 supplementation in elderly people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Medicine 2005;165:1167-1172. 60 Clarke R, Frost C, Sherliker P, Lewington S, Collins R, for the Homocysteine-Lowering
Trialists’ Collaboration. Dose-dependent effects of folic acid on plasma homocysteine concentrations. A meta-analysis of the randomised trials. Am J Clin Nutr 2005;82:806-812. 61 Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke.

62 Morkbak AL, Mjerde R, Emmens K, Molloy A, Hvas AM, Schneede J, Clarke R, Scott JM,
Ueland PM. Nexo E. Holotranscobalamin, measurement and clinical utility. Clin Chem Lab Med 2005;43:1058-64.
63 Lewington S, Clarke R. Combined effects of systolic blood pressure and total cholesterol on
cardiovascular disease risk. Circulation 2005;112:3373-3374. 64 Breeze E, Clarke R, Shipley MJ, Marmot MG, Fletcher AE. Cause-specific mortality in
relation to body mass index in middle age in old age. Int J Epidemiol 2006; 1-10.
65 Hin H, Clarke R et al. Clinical relevance of vitamin B12 in older people: Banbury B12
study. Age and Aging 2006; 35:416-22.
66 Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, Parish S, Palmer A, Cardon L,
Peto R, Lathrop M, Collins R for the International Study of Infarct Survival (ISIS) Collaborators. Lymphotoxin-alpha gene (LTA) and risk of myocardial infarction in 6928 cases and 2712 controls in the ISIS case-control study. PloS Genetics 2006e,107.
67 R Clarke, J Armitage, S Lewington, P Sherliker, R Collins for the Homocysteine-lowering
Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282-7.
68 Farrall M, Green FR, Peden JF, Olsson PG, Clarke R, Hellenius ML, Rust S, Lagercrantz J,
Schulte H, Carey A, Olsson GO, Assmann G, Tognoni G, Collins R, Hamsten A, Watkins H. Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS-Genetics 2006 e72.
69 Clarke R. Vitamin B12, folic acid, and the prevention of dementia. N Engl J Med 2006;
70 Clarke R, Lewington S. Trans fatty acids and coronary heart disease. Food labels should
list these as well as cholesterol and saturated fat. Br Med J 2006; 333; 214.
2007

71 Clarke R, Emberson J, Armitage J, Shipley M, Clark S, Linksted P , Fletcher A, Col ins
R. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. Arch Internal Medicine 2007;167: 1373-8.
72 Neville MN, Clarke R, JG Evans, Karpe G. Absence of relationship between MTP
haplotypes and longevity. J Gerontol A Biol Sci Med Sci. 2007;62:202-5. 73 Devlin AM, Clarke R, Birks J, Evans JE, Halsted CH. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine levels in healthy elderly population. Am J Clin Nutr 2006; 83:708-13.
74 Eussen SJ, deGroot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, Schneede J, Blom
HJ, Hoefnagels WH, van Staveren WA. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006; 84:361-70.
75 Clarke R, Lewington S, Sherliker P, Armitage J. Effects of B-vitamins on plasma
homocysteine concentrations and on risk of cardiovascular disease and dementia. Current Opinion in Nutrition and Metabolism 2007;10:32-39.
76 Clarke R. Homocysteine, B-vitamins and risk of dementia. A J Clin Nutr 2007; 85: 329-330
77 Ueland PM, Clarke R. Homocysteine and cardiovascular risk: considering the evidence in
the context of study design, folate fortification, and statistical power. Clin Chem 2007; 53: 1-3.
78 R Clarke. Homocysteine-lowering vitamin B supplements do not improve cognitive
performance in healthy older adults after two years. Evid Based Ment Health 2007;10: 27.
79 Clarke R, Birks J, Nexo E, Ueland PM, Schneede PM, Scott J, Molloy A, Frost C, Evans
JM. Low vitamin B12 status and risk of cognitive decline in older people. Am J Clin Nutr 2007 ;86(5):1384-91.
80 Baigent C, Clarke R. Cholesterol and lipids. International encylopaedia of public health

81 Baigent C, Clarke R. B vitamins for the prevention of vascular disease: insufficient
evidence to justify treatment. JAMA. 2007;298:1212-4.
82 Eussen SJ, Ueland PM, Clarke R, Blom HJ, Hoefnagels WH, van Staveren WA, de Groot
LC. The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people. Br J Nutr. 2007;98: 960-8. 83 Clarke R, Shipley M, Breeze E, Collins R, Marmot M, Halsey J, Fletcher A, Hemingway
H. Survival in relation to angina symptoms and diagnosis among men aged 70-90 years: the Whitehall Study. Eur J Cardiovasc Prev Rehabil 2007;14: 280-6. 84 Clarke R, Sherliker P, Hin H, Nexo E, Hvas AM, Schneede J, Birks J, Ueland PM,
Emmens K, Scott JM, Molloy AM, Evans JG. Detection of vitamin B12 deficiency in older people by measuring vitamin B12 or the active fraction of vitamin B12, holotranscobalamin. Clin Chem 2007;53(5):963-70. 85 Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto
R, Collins R n behalf of the Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual participant data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-39.
2008

86 Clarke R. Cholesterol fractions and heart disease mortality in older men. Cardiology

87 Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, Clarke R, Collins R,
Franzosi MG, Tognoni G, Seedorf U, Rust S, Eriksson P, Hamsten A, Farrall M, Watkins H, PROCARDIS consortium.Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet. 2008;17(6):806-14. 88 Clarke RJ, Bennett DA. B vitamins for prevention of cognitive decline: insufficient
evidence to justify treatment. JAMA 2008;300(15):1819-21. 89 Cluett C, Brayne C, Clarke R, Evans G, Matthews F, Rubinsztein DC, Huppert F,
Llewellyn DJ, Rice N, Henley W, Frayling TM, Murray A, Melzer D. Polymorphisms in LMNA and near a SERPINA gene cluster are associated with cognitive function in older people Neurobiol Aging. 2008; 8. 90 Winkels RM, Brouwer IA, Clarke R, Katan MB, Verhoef P. Bread cofortified with folic acid
and vitamin B-12 improves the folate and vitamin B-12 status of healthy older people: a randomized controlled trial. Am J Clin Nutr. 2008; 88(2):348-55.
91 Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I,
Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008 (8):683-9.
92 Dangour AD, Breeze E, Clarke R, Shetty PS, Uauy R, Fletcher AE. Plasma
homocysteine, but not folate or vitamin B-12, predicts mortality in older people in the United Kingdom. J Nutr 2008; 138:1121-8. 93 Clarke R, Sherliker P, Hin H, Molloy AM, Nexo E, Ueland PM, Emmens K, Scott JM,
Evans JG. Folate and vitamin B12 status in relation to cognitive impairment and anaemia in the setting of voluntary fortification in the UK. Br J Nutr 2008; 100:1054-9.
94 Clarke R, Emberson JR, Breeze E, Casas JP, Parish S, Hingorani AD, Fletcher A, Collins
R, Smeeth L. Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. Eur Heart J. 2008;29: 800-9. 95 Clarke R. B-vitamins and prevention of dementia. Proc Nutr Soc. 2008;67(1):75-81.
Bennett DA, Xu P, Clarke R, Zondervan K, Parish S, Palmer A, Cardon L, Peto R,
Lathrop M, Collins R; International Study of Infarct Survival Collaborators. The exon 1-
8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of
myocardial infarction in 6946 cases and 2720 controls from a United Kingdom
population. Eur J Hum Genet. 2008;16: 480-6.
Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC,
Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F,
Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan
P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall
J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G,
Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS,
Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly
identified loci that influence lipid concentrations and risk of coronary artery disease.
Nat Genet 2008; 40:161-9.
CRP CHD Genetics Collaboration. Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. Eur J Epidemiol 2008; 23: 531-540. Gasowski J, Li Y, Kuznetsova T, Richart T, Thijs L, Grodzicki T, Clarke R, Staessen
JA. Is “usual” blood pressure a proxy for 24-hr ambulatory blood pressure in predicting
cardiovascular outcomes? Am J Hypertension 2008; 21: 994-100.
100 The SEARCH Collaborative Group. SLCOIB1 variants and statin-induced myopathy. 101 Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti
A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA,
Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J,
Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J,
Debakker PI, O'Donnell CJ, Chambers JC, Kooner JS, Hercberg S, Meneton P, Lakatta
EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins
R, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordovas JM,
Boehnke M, Abecasis GR, Mohlke KL, Cupples LA. Common variants at 30 loci
contribute to polygenic dyslipidemia. Nat Genet 2009; 41:56-65.
102 Clarke R. Brain. In Stanner S (Editor), Diet, Nutrition and Ageing. British Nutritional
Foundation, London. Blackwell Scientific Publications 2009.
103 Clarke R, Emberson J, Fletcher A, Breeze E, Marmot M, Shipley M J. Life expectancy
in relation to cardiovascular risk factors: 38 year follow-up of 19000 men in the Whitehall Study. BMJ 2009; 339: b 3513 doi: 104136/bmj.63513. 104. Malarstig A, Buil A, Souto J C, Clarke R, Blanco Vaca F, Fonticuberta J, Peden J,
Anderson M, Silveira A, Barlera S, Seedorf A, Watkins H, Almasy L, Hamsten A, Soria J M, on behalf of the Genetic Analysis of Idiopathic Thrombophilia (GAIT) and Precocious Coronary Artery Disease (PROCARDIS) consortia. Blood 2009; 114: 1417 – 22. 105. Elliott P, Chambers J C, Zhang W, Clarke R, Hopewell J C, Peden J F et al. Genetic
loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302: 37-48. 106. Barton R H, Waterman D, Bonner F W, Holmes E, Clarke R, the PROCARDIS
consortium, Nicholson J K, London J C. The influence of EDTA not citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. Molecular Biosystems 2010;DOI:10.1039/b907021d 107. Emerging Risk Factors Collaboration. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke and non-vascular mortality. JAMA 2009; 302: 412-23. 108. Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, Whitlock G, Clark S,
Youngman L, Sleight P, Collins R for the International Studies of Infarct Survival Collaborators. Eur Heart J 2009; 30: 2137-46. 109. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N,
Collins R, Peto R. Body mass index and cause-specific mortality in 900,000 adults: col aborative analysis of 57 prospective studies. Lancet 2009, 373: 1083-96. 110. Peters R, Beckett N, Forette A, Tuomilehto J, Ritchie C, Walton I, Waldman A, Clarke
R, Poulter R, Fletcher A, Bulpitt C. Int J Psychogeriatr 2009; 21: 359-68.
111. Mozaffarian D, R Clarke. Quantitative effects on cardiovascular risk factors and
coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr 2009 63:s22-33. 112. Uauy R, Aro A, Clarke R, Ghafoorunissa R, L’Abbé MR, Mozaffarian D, Skeaff M,
Stender S and Tavella M. WHO Scientific Update on trans fatty acids: summary and conclusions. Eur J Clin Nutr. 2009; 63:568-575. 113. Batty GB, Kivimaki M, Morrison D, Huxley R, Smith GD, Clarke R, Marmot M, Shipley
MJ. Cancer Epidemiol Biomarkers Prev 2009; 18:673-5. 114. Newhouse S, Wallace C, Hoti M, Burke B, Howard P, Onipinla A, Lee K, Shaw- Hawkins S, Dobson R, Farrall M, Brown M, Samani N, Dominiczak A, Connell JM,
Webster J, Lathrop M, Kooner J, Chambers J, Elliott P, Clarke R, Laan M Org E,
Eyheramendy S, Veldre G, Viigimaa M, Cappuccio FP, Ji C, Iacone R, Strazzullo P,
Kumari M, Marmot M, Brunner E, Caulfield M and Munroe P. Polymorphisms in the
WNK1 gene are significantly associated with blood pressure, hypertension and urinary
potassium levels. PLoS-Genetics 2009; 4: c5003.
115. Newton-Cheh C, Johnson T, Gateva V, Tobin M, Bochud M, Coin L, Najjar S, Hua Zhao J, Heath S, Eyheramendy S, Papadakis K, Voight B, Scott L, Zhang F, Farrall M,
Tanaka T, Wallace C, Chambers J, Khaw K, Nilsson P, van der Harst P, Polidoro S,
Grobbee D, Onland-Moret N, Bots M, Wain L, Elliott K, Teumer A, Luan J, Lucas G,
Kuusisto J, Burton P, Hadley D, McArdle W, Wel come Trust Case Control Consortium,
Brown M, Dominiczak A, Newhouse S, Samani N, Webster J, Zeggini E, Beckmann J,
Bergmann S, Lim N, Song K, Vollenweider P, Waeber G, Waterworth D, Yuan X, Groop
L, Orho-Melander M, Allione A, Gregorio A, Guarrera S, Panico S, Ricceri F,
Romanazzi V, Sacerdote C, Vineis P, Barroso I, Sandhu M, Luben R, Boehnke M,
Bonnycastle L, Collins F, Jackson A, Mohlke K, Stringham H, Valle T, Willer C,
Bergman R, Morken M, Döring A, Gieger C, Illig T, Lichtner P, Meitinger T, Org E,
Wichmann H, Kathiresan S, Marrugat J, O'Donnell C, Salomaa V, Schwartz S,
Siscovick D, Subirana I, Freimer N, Hartikainen A, McCarthy M, O’Reilly P, Peltonen L,
Pouta A, de Jong P, Snieder H, van Gilst W, Clarke R, Goel A, Hamsten A, Peden J,
Seedorf U, Syvänen A, Tognoni G, Lakatta E, Sanna S, Scheet P, Schlessinger D,
Scuteri A, Dörr M, Ernst F, Felix S, Homuth G, Lorbeer R, Reffelmann T, Rettig R,
Völker U, Galan P, Gut I, Hercberg S, Lathrop G, Zeleneka D, Deloukas P, Soranzo N,
Williams F, Zhai G, Laakso M, Elosua R, Forouhi N, Völzke H, Uiterwaal C, van der
Schouw Y, Numans M, Matullo G, Navis G, Berglund G, Bingham S, Kooner J,
Paterson A, Connell J, Bandinelli S, Ferrucci L, Watkins H, Spector T, Tuomilehto J,
Altshuler D, Strachan D, Laan M, Meneton P, Wareham N, Uda M, Jarvelin M, Mooser
V, Melander O, Loos R, Elliott P, Abecasis G, Caulfield M, Munroe P. Nine blood
pressure loci identified by genome-wide association study of 34,433 people of European ancestry. Nature Genetics 2009 41: 666-676. 116. Clarke R, Armitage J. Greater absolute reductions in LDL cholesterol should yield
greater proportional reductions in risk of cardiovascular disease. J Intern Med 2009 (In Press). 117. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke and mortality. The Lancet 2009 (In Press). 118. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular 119. Chasman D I, Pare G, Mora S, Hopewell JC, Peloso G, Clarke R, Cupples L A,
Hamsten A, Kathiresan J, Malarstig A, Ordouns J M, Ripatti S, Parker A N, Miletich J P, Ridker P M. Forty three loci associated with plasma lipoprotein size, concentration and cholesterol content in genome-wide analysis. (In Press).

Source: http://www.cardioscience.ox.ac.uk/bhf-centre-of-research-excellence/researcher-profiles/Clarke%20publications.pdf

S:\yvonnek\my documents\web page\solidarity\solidarityykk.wpd

It’s Flu Season: Prescription? contact WPS Customer Service. WPS’ pharmacy analyst willwork with the pharmacy to confirm that coverage criteria aremet. If one meets eligibility, WPS will arrange a refund by the One needs no reminder that it is flu season . One also need not be reminded that flu shots - for seasonal flu and moreparticularly for H1N1 - are in short supply. Given this, som

cbcsq.qc.net

Le trouble déficitaire d’attention avec hyperactivité : un facteur significatif de violence Michel Parisien Si le trouble déficitaire d’attention avec hyperacti- vité (TDA-H) est un facteur significatif de violence, c’est à cause de son essence même : un déficit du contrôle de soi. C’est d’ailleurs non seulement un problème majeur parce qu’il peut générer la vio

Copyright © 2010-2018 Pharmacy Drugs Pdf